Programming Immune Cells to Fight Cancer with New Vaccines
Rational in situ programming of cancer vaccine-responding T-cell clones
This project is creating tiny injectable tools to help your body's immune cells learn how to find and destroy cancer cells more effectively.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Fred Hutchinson Cancer Center NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-11083733 on NIH RePORTER |
What this research studies
Currently, doctors face challenges in quickly building strong T-cell immunity against cancer, as existing vaccines often fail because patients lack enough of the right immune cells. This project aims to solve this by developing injectable nanoreagents that can introduce specific instructions into your T-cells. The goal is to combine anti-cancer vaccines with these special particles to program your immune cells, including helper T-cells, to mount a stronger and more targeted attack against tumors. Researchers have already shown that these nanoparticles can successfully deliver genes to T-cells, enabling them to recognize cancer vaccine targets.
Who could benefit from this research
Good fit: Patients with various types of cancer who might benefit from enhanced T-cell immunity against their tumors could be ideal candidates for future applications of this research.
Not a fit: Patients whose cancer does not present suitable antigens for T-cell targeting or who cannot receive vaccine-based therapies may not receive direct benefit from this specific approach.
Why it matters
Potential benefit: If successful, this could lead to new, more effective cancer vaccines that rapidly and reliably train a patient's immune system to fight their specific tumor.
How similar studies have performed: The multidisciplinary team has already demonstrated that injected nanoparticles can deliver engineered T-cell receptor genes into host T cells to recognize cancer vaccine antigens, indicating some foundational success.
Where this research is happening
Seattle, United States
- Fred Hutchinson Cancer Center — Seattle, United States (Active)
Researchers
- Principal investigator: Stephan, Matthias — Fred Hutchinson Cancer Center
- Study coordinator: Stephan, Matthias
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.